Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Science ShareTwitterFacebookXingLinkedin cardiovascular diseaseChronic kidney diseasediabetesGLP-1 receptor agonistHeart failureLiving guidelinesMineralocorticoid receptor antagonistObesitySGLT2 inhibitorTirzepatide You May Also Like Science 25. Mai 2023 CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes Science 25. Mai 2023 Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies. Science 25. Mai 2023 (Bersacapavir) In Participants With Moderate Hepatic Impairment.
